IRADIMED Q3 revenue $18.3M (+11% YoY), raises FY EPS guidance, declares $0.15 dividend

IRADIMED CORP

2024-Q3 EPS reported $1.10 revenue$53,852,954

Record Q3 revenue of $18.3M, up 11% YoY from $16.5M; GAAP diluted EPS $0.40, Non-GAAP $0.43.
Raises FY 2024 GAAP EPS guidance to $1.49-$1.52 (from $1.37-$1.47) and Non-GAAP to $1.64-$1.67 (from $1.52-$1.62).
Declares regular quarterly cash dividend of $0.15/share, payable Nov 25, 2024 to holders of record Nov 15, 2024.
Q3 cash flow from operations was $9.1M, vs $1.4M in prior year; new Orlando facility capex ~$9M remaining.
Q4 2024 guidance: revenue $18.8M-$19.2M, GAAP EPS $0.39-$0.42, Non-GAAP EPS $0.42-$0.45.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.